Senti Biosciences (SNTI) appoints Feng Hsiung to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Senti Bio Appoints Feng Hsiung to Board of Directors
March 13, 2025 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio, or the Company), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the Board).
We are pleased to welcome Feng to our Boardhe brings deep expertise in investment strategy and capital markets across multiple industries, said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. We look... More
